期刊文献+

3-BrPA对肺癌A549/DDP细胞耐药的逆转作用研究 被引量:1

Experimental study of 3-BrPA on reversing multidrug resistance of human lung cancer cell line A549/DDP
原文传递
导出
摘要 目的探究3-Br PA对肺癌A549/DDP细胞耐药的逆转作用及其机制。方法 1细胞培养:RPMI1640培养基培养肺癌A549细胞及人肺腺癌耐顺铂细胞株A549/DDP细胞;2采用CCK8及Western blot法观察3-Br PA对A549/DDP细胞的耐药逆转作用和P-糖蛋白(P-glycoprote,P-gp)的表达水平;采用流式细胞术检测不同浓度3-Br PA作用A549/DDP细胞后细胞内罗丹明-123(Rhodamine-123,Rh123)的蓄积情况。结果顺铂对A549细胞、A549/DDP细胞及3-Br PA作用后的A549/DDP细胞的IC50分别为6.714μg/ml、38.99μg/ml及12.86μg/ml,逆转倍数为3.03,相对逆转效率为81%。3-Br PA可使A549/DDP细胞的P-gp表达下调。3-Br PA可使A549/DDP细胞内的Rh123蓄积增多并呈剂量依赖性。结论 3-Br PA可逆转A549/DDP细胞对顺铂耐药,作用机制可能与其抑制P-gp的功能和表达有关。 Objective To preliminarily explore the reversal effect of 3-Br PA on multidrug resistance of lung cancer cell line A549/DDP and to study its potential mechanism. Methods ①Cell culture: The human lung adenocarcinoma cell line A549 and cisplatin-resistant cell line A549/DDP cells were grown in RPMI1640 medium; ②CCK8 and Western blot were used to observe the reversal effect of 3-Br PA on cisplatin-resistant cell line A549/DDP cells and the expression of P-gp. Flow cytometric technology was used to detect different concentrations of 3-Br PA on A549/DDP cells by measuring Rh123 mean fluorescence intensity( MFI). Results The IC50 of cisplatin to A549 cells,A549/DDP cells and A549/DDP cells after 3-Br PA added were 6.714 μg/ml,38.99 μg/ml and 20.2 μg/ml,respectively. The reversal ratio was 3.03 and the relative reversal efficiency was 81% as compared to A549 cells; The 3-Br PA can make the expression of P-gp on A549/DDP cells dropped. The result of FCM shows that 3-Br PA can increase the accumulation of Rh123 on A549/DDP cells in a dose-dependent manner. Conclusions 3-Br PA can reverse the drug resistance on A549/DDP cell line to cisplatinum in a certain extent,which may be attributed to down regulating of P-gp expression.
作者 唐青 胡义德
出处 《中华肺部疾病杂志(电子版)》 CAS 2016年第2期145-149,共5页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家自然科学基金资助项目(81372340)
关键词 支气管肺癌 3-BrPA A549/DDP细胞 耐药逆转 Bronchus lung cancer 3-BrPA Cisplatin-resistant cell line A549/DDP cells Resistance reversal
  • 相关文献

参考文献17

  • 1钱桂生.肺癌不同病理类型发病率的变化情况及其原因[J].中华肺部疾病杂志(电子版),2011,4(1):1-5. 被引量:218
  • 2尹丽慧,叶爱芳,熊术道,韩义香,章圣辉,吴建波.苦瓜蛋白对K562/A02耐药逆转作用的研究[J].浙江中医药大学学报,2009,33(4):475-477. 被引量:4
  • 3Silva R, Vilas-BoasV, Carmo H, et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy [ J]. Pharmacol Ther, 2015, 149: 1-123.
  • 4Li XQ, Wang L, Lei Y, et al. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivativesuropean [ J ]. Eur J Med Chem, 2015, 101 : 560-572.
  • 5Wang YJ, Kathawala RJ, Zhang YK, et al. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1 [ J ]. Biochem Pharmacol, 2010, 90(4): 367-378.
  • 6Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective Pglycoprotein inhibitor, in patients with chemotherapy- resistant, advanced breast carcinoma[ J]. Cancer, 2005, 104(4): 682-691.
  • 7吴弄,邓媛媛,徐俊,蔡绍晖.3-溴丙酮酸肿瘤多药耐药逆转剂的研究进展[J].华西药学杂志,2013,28(4):421-424. 被引量:3
  • 8Pedersen PL.3-Bmmopyruvate (3BP) a fast acting, promising, powerful, specific, and effective" small molecule" anti-cancer agent taken from labside to bedside : introduction to a special issue [ J ]. J Bioenerg Biomembr, 2012, 44(1) : 1-6.
  • 9Schaefer NG, Geschwind JF, Engles J, et al. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma [J]. Transl Res, 2012, 159(1): 51-57.
  • 10lhrlund LS, Hernlund E, Khan O, et al. 3-Bromopyruvate as inhibitor turnout cell energy metabolism and chemopotentiator of platinum drugs[J]. Mol Oncol, 2008, 2(1): 94-101.

二级参考文献68

共引文献235

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部